- Home
- ESPR vs GBAB Comparison
ESPR vs GBAB Comparison
Compare ESPR & GBAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- GBAB
- Stock Information
- Founded
- ESPR 2008
- GBAB 2010
- Country
- ESPR United States
- GBAB United States
- Employees
- ESPR N/A
- GBAB N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- GBAB Investment Managers
- Sector
- ESPR Health Care
- GBAB Finance
- Exchange
- ESPR Nasdaq
- GBAB Nasdaq
- Market Cap
- ESPR 410.2M
- GBAB 387.9M
- IPO Year
- ESPR 2013
- GBAB N/A
- Fundamental
- Price
- ESPR $1.89
- GBAB $15.82
- Analyst Decision
- ESPR Buy
- GBAB
- Analyst Count
- ESPR 6
- GBAB 0
- Target Price
- ESPR $7.25
- GBAB N/A
- AVG Volume (30 Days)
- ESPR 5.1M
- GBAB 69.4K
- Earning Date
- ESPR 02-25-2025
- GBAB 01-01-0001
- Dividend Yield
- ESPR N/A
- GBAB 9.18%
- EPS Growth
- ESPR N/A
- GBAB N/A
- EPS
- ESPR N/A
- GBAB N/A
- Revenue
- ESPR $295,451,000.00
- GBAB N/A
- Revenue This Year
- ESPR $186.04
- GBAB N/A
- Revenue Next Year
- ESPR $11.25
- GBAB N/A
- P/E Ratio
- ESPR N/A
- GBAB N/A
- Revenue Growth
- ESPR 187.12
- GBAB N/A
- 52 Week Low
- ESPR $1.58
- GBAB $14.22
- 52 Week High
- ESPR $3.94
- GBAB $17.44
- Technical
- Relative Strength Index (RSI)
- ESPR 39.38
- GBAB 62.03
- Support Level
- ESPR $1.71
- GBAB $15.50
- Resistance Level
- ESPR $2.26
- GBAB $15.86
- Average True Range (ATR)
- ESPR 0.14
- GBAB 0.17
- MACD
- ESPR -0.01
- GBAB 0.04
- Stochastic Oscillator
- ESPR 33.33
- GBAB 86.44
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About GBAB Guggenheim Taxable Municipal Bond & Investment Grade Debt Trust of Beneficial Interest
Guggenheim Taxable Municipal Managed Duration Trust is a diversified closed-end management investment company. Its investment objective is to provide current income with a secondary objective of long-term capital appreciation. Its products include Mutual funds, Unit investment trusts, Closed-end funds, Rydex funds, Credit income fund and others.